The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of insurance payer status (IS) on practice patterns and overall survival (OS) in patients (pts) with metastatic urothelial carcinoma (mUC).
 
Benjamin D. Mercier
No Relationships to Disclose
 
Nishita Tripathi
No Relationships to Disclose
 
Ameish Govindarajan
No Relationships to Disclose
 
Georges Gebrael
No Relationships to Disclose
 
Arshit Narang
No Relationships to Disclose
 
Xiaochen Li
No Relationships to Disclose
 
Daniela V. Castro
No Relationships to Disclose
 
Alex Chehrazi-Raffle
Honoraria - OncLive/MJH Life Sciences
Consulting or Advisory Role - Tempus
Research Funding - Exelixis
 
Nazli Dizman
Stock and Other Ownership Interests - Biofarma Ilac (I)
Consulting or Advisory Role - Vivreon Biosciences
 
Hedyeh Ebrahimi
No Relationships to Disclose
 
Neal Shiv Chawla
No Relationships to Disclose
 
Joann Hsu
No Relationships to Disclose
 
Cristiane Decat Bergerot
No Relationships to Disclose
 
Regina Barragan-Carrillo
No Relationships to Disclose
 
Zeynep Busra Zengin
No Relationships to Disclose
 
Luis A Meza
Honoraria - Ipsen
Travel, Accommodations, Expenses - Ipsen; Ipsen
 
Sumanta Kumar Pal
Travel, Accommodations, Expenses - crispr therapeutics; Exelixis; Ipsen
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer
 
Abhishek Tripathi
Honoraria - Cardinal Health; Targeted Oncology; Urology times
Consulting or Advisory Role - AADi; Deka Biosciences; EMD Serono; Exelixis; Exelixis; Foundation Medicine; Genzyme; Pfizer; Seagen; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Research Funding - Aravive (Inst); Bayer (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); EMD Serono (Inst); Exact Sciences (Inst); Exelixis (Inst); Pfizer (Inst); WindMIL (Inst)